Bharath Krishnamurthy, director of health policy and analytics, American Hospital Association, explains factors leading to the economic instability of the U.S. healthcare system. 

The drugmaker argues that the FDA's recent approval of a generic version of Entresto should not be allowed for multiple reasons. Novartis sent multiple requests to the agency hoping to stop the approval, but the FDA denied each one. 

Compounded semaglutide injectable products are at the heart of these concerns. While the FDA says compounded drugs “can serve an important medical need for patients,” the agency does not approve these new formulations, increasing the risk of complications. 

Businesses in the cardiovascular health space have been busy in recent weeks, announcing one big financing round after another. 

The American Medical Association has a collection of artifacts on health fraud quackery at its Chicago headquarters office.

The popular drugs, originally developed to treat diabetes, are being used more and more in the United States to help obese and overweight patients lose weight.  

Improving care for patients with cardiac amyloidosis has emerged as one of the hottest topics in cardiology. Pfizer helped kickstart that trend in 2019 when it gained FDA approval for two separate medications for the rare, but potentially fatal disease. 

While GLP-1 drugs were originally developed to treat diabetes, researchers keep finding additional ways these medications can potentially benefit patients.